

eTable 4: Consensus QUADAS-2 assessment and inter-rater reliability

	Patient selection			Index test		Reference standard	Flow and timing				Applicability			
	Sampling	Study design	Exclusion criteria	Blinding	A priori cutoff	Clinical diagnosis	Blinding	Time interval	Equal treatment	Final analysis	Missing values	Representativity	Repeatability	Recency
Abu-Rumeileh et al. 2019 ¹														
Baldeiras et al. 2009 ²														
Bizzi et al. 2020 ³														
Bongianni et al. 2017 ⁴												†		
Chohan et al. 2010 ⁵														
Cuadrado-Corrales et al. 2006 ⁶														
Fiorini et al. 2020 ⁷														
Franceschini et al. 2017 ⁸														
(Hamlin et al. 2012 ⁹)														
Lattanzio et al. 2017 ¹⁰				*										
Leitão et al. 2016 ¹¹														
Otto et al. 2002 ¹²														
Rhoads et al. 2020 ¹³														
(Rudge et al. 2018 ¹⁴)														
Sanchez-Juan et al. 2006 ¹⁵														
Simon et al. 2020 ¹⁶														
Van Everbroeck et al. 2003 ¹⁷														
(Wang et al. 2013 ¹⁸)														
Zerr et al. 1998 ¹⁹														
Krippendorff's alpha	0.20	0.28	0.77	0.33	0.51	-0.04	0.26	0.20	0.51	0.41	0.22	-0.24	-0.12	-0.08

= high risk of bias / poor applicability
 = unclear risk of bias / limited applicability
 = low risk of bias / good applicability

*

 = low and high risk of bias next to each other (high risk of bias used in further analyses)

†

 = good and limited applicability next to each other (limited applicability used in further analyses)

(X)

 = not included in quantitative analyses

X

 = authors answered inquiries

References:

1. Abu-Rumeileh S, Baiardi S, Polischi B, et al. Diagnostic value of surrogate CSF biomarkers for Creutzfeldt–Jakob disease in the era of RT-QuIC. *J Neurol.* 2019;266:3136–3143.
2. Baldeiras IE, Ribeiro MH, Pacheco P, et al. Diagnostic value of CSF protein profile in a Portuguese population of sCJD patients. *J Neurol.* 2009;256:1540–1550.

3. Bizzi A, Pascuzzo R, Blevins J, et al. Evaluation of a New Criterion for Detecting Prion Disease With Diffusion Magnetic Resonance Imaging. *JAMA Neurol.* 2020;77:1141.
4. Bongianni M, Orrù C, Groveman BR, et al. Diagnosis of Human Prion Disease Using Real-Time Quaking-Induced Conversion Testing of Olfactory Mucosa and Cerebrospinal Fluid Samples. *JAMA Neurol.* 2017;74:155.
5. Chohan G, Pennington C, Mackenzie JM, et al. The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review. *J Neurol Neurosurg Psychiatry.* 2010;81:1243–1248.
6. Cuadrado-Corrales N, Jiménez-Huete A, Albo C, et al. Impact of the clinical context on the 14-3-3 test for the diagnosis of sporadic CJD. *BMC Neurol.* 2006;6:25.
7. Fiorini M, Iselle G, Perra D, et al. High diagnostic accuracy of RT-QuIC assay in a prospective study of patients with suspected sCJD. *Int J Mol Sci.* 2020;21:1–10.
8. Franceschini A, Baiardi S, Hughson AG, et al. High diagnostic value of second generation CSF RT-QuIC across the wide spectrum of CJD prions. *Sci Rep.* 2017;7:10655.
9. Hamlin C, Puoti G, Berri S, et al. A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease. *Neurology.* 2012;79:547–552.
10. Lattanzio F, Abu-Rumeileh S, Franceschini A, et al. Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and A β 42 levels. *Acta Neuropathol.* 2017;133:559–578.
11. Leitão MJ, Baldeiras I, Almeida MR, et al. Sporadic Creutzfeldt–Jakob disease diagnostic accuracy is improved by a new CSF ELISA 14-3-3 γ assay. *Neuroscience.* 2016;322:398–407.
12. Otto M, Wiltfang J, Cepek L, et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. *Neurology.* 2002;58:192–197.
13. Rhoads DD, Wrona A, Foutz A, et al. Diagnosis of prion diseases by RT-QuIC results in improved surveillance. *Neurology.* 2020;95:e1017–e1026.
14. Rudge P, Hyare H, Green A, Collinge J, Mead S. Imaging and CSF analyses effectively distinguish CJD from its mimics. *J Neurol Neurosurg Psychiatry.* 2018;89:461–466.
15. Sanchez-Juan P, Green A, Ladogana A, et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. *Neurology.* 2006;67:637–643.
16. Simon SLR, Peterson A, Phillipson C, et al. Prospective Study Demonstrates Utility of EP-QuIC in Creutzfeldt–Jakob Disease Diagnoses. *Can J Neurol Sci.* 2021;48:127–129.
17. Van Everbroeck B, Quoilin S, Boons J, Martin JJ, Cras P. A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. *J Neurol Neurosurg Psychiatry.* 2003;74:1210–1214.
18. Wang LH, Bucelli RC, Patrick E, et al. Role of magnetic resonance imaging, cerebrospinal fluid, and electroencephalogram in diagnosis of sporadic Creutzfeldt-Jakob disease. *J Neurol.* 2013;260:498–506.
19. Zerr I, Bodemer M, Gefeller O, et al. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. *Ann Neurol.* 1998;43:32–40.